IMMUNOSCORE®
Scoring Immune Response in Colon Cancer
for unmatched clinical performance in routine settings

Patient survival fate is dependent
on preexisting immunity

Dr. Jérôme Galon, Head of the Integrative Cancer Immunology
at the Cordeliers Research Center in Paris, France
**WHY IMMUNOSCORE®**

Immunoscore® is an in vitro diagnostic test predicting the risk of relapse in localized colon cancer patients, by measuring the host immune response at the tumor site. It is a risk-assessment tool that provides independent and superior prognostic value than the usual tumor risk parameters, and should be used as an adjunct to the TNM classification (Pagès F et al. The Lancet 2018, Sinicrope F et al. J Clin Oncol 2018). Immunoscore® can thus improve individual patient treatment strategies, particularly the modulation of adjuvant chemotherapy in stage II and stage III.

Largest contribution of Immunoscore® (47%) to survival risk

---

**WHY IMMUNOSCORE®**

Immunoscore® can improve individual patient treatment strategies, particularly the modulation of adjuvant chemotherapy in stage II and stage III. Immunoscore® can thus improve individual patient treatment strategies, particularly the modulation of adjuvant chemotherapy in stage II and stage III.

---

**CLINICAL UTILITY IN LOCALIZED COLON CANCER**

**IMMUNOSCORE® FOR STAGE II CC PATIENTS**

In the large Immunoscore® SITC study (more than 2,500 stage I-III patients), Immunoscore® was strongly predictive of the patient outcome and surpassed the TNM classification prognostic performance.

**Focusing on stage II (n = 1,434 patients),** Immunoscore® identified a subgroup of high-risk (Immunoscore® Low) stage II patients (27%) who may benefit from chemotherapy.

---

**IMMUNOSCORE® FOR STAGE III CC PATIENTS**

Following international IDEA collaboration results, it has been suggested that the duration of adjuvant FOLFOX or CAPOX chemotherapy should be guided by a risk-based approach, based on T and N risk groups (T1-3 N1 versus T4 or N2).

Immunoscore® has been tested on 600 resected tumors of stage III CC patients from the FOLFOX arm of the prospective NCTCTG N0147 clinical trial. This retro-prospective study demonstrated that Immunoscore Low was associated with a higher risk of recurrence including among the low risk T1-3 N1 subgroup with significantly worse 3-years DFS (78% vs. 92%, see figure on the right). These data underscore the limitations of T and N staging and provide validation for Immunoscore® to identify high risk T1-3 N1 patients for whom a 3 months chemotherapy course might be detrimental.

---

**IMMUNOSCORE® WORKFLOW**

Immunoscore® is available as a full service solution (performed in HalioDx laboratories).

---

**MAIN FEATURES...**

CLINICAL UTILITY
- Improved estimation of risk of relapse for St II & St III colon cancer patients

MATERIAL
- FFPE block or FFPE slides from tumor resection

TARGET
- CD3+ & CD8+ T-cells

LOCATION
- Center and periphery of the tumor

TECHNOLOGY
- Image Analysis